Elinzanetant 60 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 60 mg

Reference Brands: Lynkuet (USA/EU)

Category: Women's Health

Elinzanetant is a non‑hormonal neurokinin‑1 and neurokinin‑3 (NK1 and NK3) receptor antagonist used for the treatment of moderate to severe vasomotor symptoms (hot flashes and night sweats) associated with menopause or with hormone‑suppressive therapy in women. It works by blocking brain receptors involved in regulation of body temperature and sleep, thereby reducing the frequency and severity of hot flashes and may also help improve sleep disturbances common during menopause.

Product Description:

Elinzanetant blocks two neurokinin receptors, NK1 and NK3. Hot flushes originate in a group of hypothalamic neurons that control the body's temperature set point; when oestrogen falls at menopause those neurons become overactive, and neurokinin B signalling through NK3 is what drives that. Blocking NK3 calms the signal, and the additional NK1 blockade is thought to contribute to the improvement in sleep that distinguishes this drug from NK3-only agents.

It is used for moderate to severe vasomotor symptoms of menopause, including in women whose symptoms are caused by endocrine therapy for breast cancer — a group for whom hormone therapy is contraindicated and who previously had few options. In trials it reduced hot flush frequency and severity substantially, with improvements in sleep disturbance and quality of life. It is taken once daily at bedtime. Liver enzyme elevations occur, so liver function is checked before treatment and periodically during the first months. Headache, fatigue and drowsiness are the common adverse effects.

Sourcing notes. Originator product, on patent, no generic. Approved in the EU and the US; other markets are following. Supply is through authorised distribution. The non-hormonal positioning and the breast cancer population are what define demand.